HomeCompareEXUS vs PFE

EXUS vs PFE: Dividend Comparison 2026

EXUS yields 0.04% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.8K in total portfolio value· pulled ahead in Year 8
10 years
EXUS
EXUS
● Live price
0.04%
Share price
$24.64
Annual div
$0.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.7K
Annual income
$3.64
Full EXUS calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — EXUS vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEXUSPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EXUS + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EXUS pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EXUS
Annual income on $10K today (after 15% tax)
$3.09/yr
After 10yr DRIP, annual income (after tax)
$3.09/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,316.81/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EXUS + PFE for your $10,000?

EXUS: 50%PFE: 50%
100% PFE50/50100% EXUS
Portfolio after 10yr
$34.6K
Annual income
$13,131.18/yr
Blended yield
37.91%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

EXUS
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EXUS buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEXUSPFE
Forward yield0.04%6.13%
Annual dividend / share$0.01$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$19.7K$49.6K
Annual income after 10y$3.64$26,258.71
Total dividends collected$36.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EXUS vs PFE ($10,000, DRIP)

YearEXUS PortfolioEXUS Income/yrPFE PortfolioPFE Income/yrGap
1$10,704$3.63$9,153$693.39+$1.6KEXUS
2$11,457$3.63$8,593$849.25+$2.9KEXUS
3$12,262$3.63$8,336$1,066.78+$3.9KEXUS
4$13,124$3.64$8,437$1,384.80+$4.7KEXUS
5$14,046$3.64$9,013$1,875.40+$5.0KEXUS
6$15,033$3.64$10,306$2,680.72+$4.7KEXUS
7$16,089$3.64$12,820$4,101.38+$3.3KEXUS
8← crossover$17,219$3.64$17,673$6,826.70$454.00PFE
9$18,428$3.64$27,543$12,591.86$9.1KPFE
10$19,722$3.64$49,560$26,258.71$29.8KPFE

EXUS vs PFE: Complete Analysis 2026

EXUSStock

The Macquarie Focused International Core ETF (EXUS) is a passively managed exchange-traded fund that tracks the MSCI World ex USA Index, providing diversified exposure to large- and mid-cap stocks outside the United States. The fund’s portfolio is heavily weighted toward the finance sector (approximately 26%) and health technology (about 10%), with the majority of assets located in Europe (59%), followed by Asia (22%) and North America (11%). Top holdings include SAP SE and ASML Holding NV. EXUS has seen strong asset growth, with assets under management reaching $2.93 billion and a one-year price performance increase of 15.64%. The ETF does not pay dividends and has a low expense ratio of 0.15%. Shares are issued by Deutsche Bank AG under the Xtrackers brand, and the fund was launched on March 6, 2024.

Full EXUS Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this EXUS vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EXUS vs SCHDEXUS vs JEPIEXUS vs OEXUS vs KOEXUS vs MAINEXUS vs JNJEXUS vs MRKEXUS vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.